Razelle Kurzrock: DART hits the target, (again)

Razelle Kurzrock shared a post on X by the Journal for ImmunoTherapy of Cancer about a recent paper by Young Kwang Chae et al. published in JITC.

“Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors”

Authors: Young Kwang Chae, Megan Othus, Christopher Ryan, Charles Blanke, Razelle Kurzrock et al.

“DART hits the target (again)”

Quoting Journal for ImmunoTherapy of Cancer’s post:

“New JITC article: Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors Young Kwang Chae, Hye Sung Kim, Elad Sharon, Razelle Kurzrock.”

Razelle Kurzrock is the Chief Medical Officer at ACT Genomics, Senior Deputy Director at the HKSH Cancer Centre, and Senior Advisor at CureScience. She is also a Professor of Medicine at the University of California, San Diego (UCSD) and the Director of the Center for Personalized Cancer Therapy at UCSD.

Additionally, Dr. Kurzrock is the founding director of the Michels Rare Cancers Research Laboratories at the MCW Cancer Center. Renowned as one of the world’s top 25 voices in precision medicine, she is celebrated for her contributions, of having over 950 scientific and medical publications.